Zanamivir, Relenza…For the prevention and treatment of influenza A and B.

New Drug Approvals



APPROVED 26-7-96……. GSK NDA 021036

A guanido-neuraminic acid that is used to inhibit neuraminidase.

Zanamivir INN /zəˈnæmɨvɪər/ is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus andinfluenza B virus. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.

The drug is approved for use for the prevention and treatment of influenza in those over the age of 7 in the United States, Canada, European Union, and many other countries. It is not recommended for people with respiratory problems and ailments.

United States6294572APPROVED  1994-12-15EXPIRY 2014-12-15
United States5360817                   1993-07-26            2013-07-26
Canada2291994 …

View original post 6,638 more words

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s